Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novo Nordisk Revenues up 11% in FY21 | Contract Pharma

What are you searching for?

Sign in
Financial News

Novo Nordisk Revenues up 11% in FY21

Obesity care sales up 50% driven by Wegovy.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Financial Report: Novo Nordisk
FY Revenues: $21.4 billion (+11%)
FY Earnings: $7.3 billion (+13%)
Comments: Operating profit increased by 8% in to $8.9 billion. Sales in International Operations increased by 12%, with sales in North America up 10%. Sales within Diabetes and Obesity care increased by 13% to $18.5 billion, driven by GLP-1 sales growth of 28% reflecting the uptake of Ozempic and Rybelsus. Obesity care sales (Saxenda and Wegovy) grew 50% to $1.3 billion and Biopharm sales increased by 1%.
 

Wegovy

In December 2021, a contract manufacturer filling syringes for Wegovy temporarily stopped deliveries and manufacturing following issues with current Good Manufacturing Practices. Consequently, fewer new weekly patient initiations are expected in the first hlf of 2022 compared to fourth quarter of 2021. Novo Nordisk still expects to be able to meet demand in the U.S. in the second half of 2022.
 
Lars Fruergaard Jørgensen, president and CEO, said, “We are very pleased with the double-digit sales growth in 2021 and the progress we have made on our Strategic Aspirations. The results reflect that almost 35 million people with diabetes are now benefiting from our treatments worldwide. In obesity, we are making progress in resolving the Wegovy supply issue and we expect to be able to meet demand from people living with obesity in the US in the second half of 2022.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters